ChinaBio Today -- In mid-summer, China lifted its IPO ban, allowing companies once again to access public markets. The first entry, a successful transaction, was Guilin Sanjin Pharmaceutical Co., which ended the year with a 41% increase. But the life science companies that listed on the ChiNext did even better -- often providing a 100% return or better. All of this is in sharp contrast to the experience of life science companies that chose to list on US exchanges. More details...
